Vera Adema Llobet
Department of Leukemia, Division of Cancer Medicine
About Dr. Vera Adema Llobet
From the beginning of my scientific career, my research interest has been in the field of bone marrow failure disorders, specifically myelodysplastic syndromes (MDS). Outcomes remain poor for certain subgroups of patients with MDS and new therapies are urgently needed. As a translational Ph.D. scientist, the major goal of my research is to clarify the pathological process and evolution of MDS to develop new targeted therapies for more effective management of patients with MDS. My current work is focused on determining dysregulated biological mechanisms that are causing the accumulation of erythroid precursors in the bone marrow of MDS patients. Our team has demonstrated that SF3B1 mutations lead to the activation of the EIF2AK1 pathway in response to heme deficiency. Using mechanistic approaches, we determined that EIF2AK1 depletion allows terminal erythroid differentiation. Based on these results, we identified EIF2AK1 as a promising therapeutic target for overcoming defective erythroid differentiation in MDS-RS patients. My multidisciplinary academic training has allowed me to deepen in the understanding of the pathogenesis of MDS. Therefore, I feel well prepared to carry out the research proposed in this application, which builds on the work that I initiated during my postdoctoral fellowship. The outcomes of this project are expected to have a significant translational and clinical impact. The combined use of genetic and pharmacological approaches will lead to the development of a novel therapeutic approach to overcoming anemia that can be quickly translated to the clinic to improve the outcomes of MDS patients.
Present Title & Affiliation
Primary Appointment
Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2016 | Autonomous University of Barcelona, Barcelona, ES, Cellular Biology, PhD |
| 2009 | Autonomous University of Barcelona, Barcelona, ES, Cellular Biology, Cytogenetic and Cancer, Master in Science |
| 2008 | Autonomous University of Barcelona, Barcelona, ES, Biology, Bachelor in Science |
Postgraduate Training
| 2020-2023 | Postgraduate Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2020 | Postgraduate Fellow, Leukemia, Cleveland Clinic, Cleveland, Ohio |
Honors & Awards
| 2024 - Present | American Society of Hematology Abstract Achievement Award, American Society of Hematology |
| 2022 | Leukemia SPORE Career Enhancement Award, The University of Texas MD Anderson Cancer Center |
| 2021 | Tito Bastianello Young Investigator Award (Basic Research), MDS Foundation |
| 2019 | Extraordinary Doctorate, Autonomous University of Barcelona |
| 2017 - Present | American Society of Hematology Abstract Achievement Award, American Society of Hematology |
| 2017 | Tito Bastianello Young Investigator Award (Translational Research), MDS Foundation |
| 2015 | Fellowship from the Spanish Society of Hematology (SEHH-FEHH), Spanish Society of Hematology (SEHH-FEHH) |
Selected Presentations & Talks
Regional Presentations
- 2023. Targeting the EIF2AK1 signaling pathway to overcome anemia in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts. Conference. Red Cells Gordon Research Conference. Newport, Rhode Island, US.
National Presentations
- 2024. Pharmacological Targeting of the Heme-Regulated Inhibitor Kinase Overcomes Ineffective Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts and Sickle Cell Disease. Conference. 66th American Society of Hematology Annual Meeting. San Diego, California, US.
- 2020. Molecular and Expression Characterization of Monosomy 7 and Del(7q). Poster. 62nd American Society of Hematology Annual Meeting. San Diego, California, US.
- 2020. Co-Existence of Splicing Factor Mutations in Myeloid Malignancies. Poster. 62nd American Society of Hematology Annual Meeting. San Diego, California, US.
- 2020. Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level. Conference. 62nd American Society of Hematology Annual Meeting. San Diego, California, US.
- 2019. CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). Poster. 61st American Society of Hematology Annual Meeting. Orlando, Florida, US.
- 2019. Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications. Poster. 61st American Society of Hematology Annual Meeting. Orlando, Florida, US.
- 2019. Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors. Poster. 61st American Society of Hematology Annual Meeting. Orlando, Florida, US.
- 2019. Can Monosomy 7 be Targeted By Next Generation Cereblon- Modulating Agents?. Poster. 61st American Society of Hematology Annual Meeting. Orlando, Florida, US.
- 2018. Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. Poster. 60th American Society of Hematology Annual Meeting. San Diego, California, US.
- 2017. Somatic PRPF8 mutations in Myeloid Neoplasia. Conference. 59th American Society of Hematology Annual Meeting. Atlanta, Georgia, US.
- 2017. Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms. Conference. 59th American Society of Hematology Annual Meeting. Atlanta, Georgia, US.
- 2016. U2AF1 Mutations in S34 and Q157 Create Distinct Molecular and Clinical Contexts. Poster. 58th American Society of Hematology Annual Meeting. San Diego, California, US.
- 2016. Molecular and Clinical Characterization of Patients with Myeloid Neoplasms Carrying the 12p Deletion. Poster. 58th American Society of Hematology Annual Meeting. San Diego, California, US.
- 2016. Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). Poster. 58th American Society of Hematology Annual Meeting. San Diego, California, US.
- 2015. The Complete Mutatome and Clonal Architecture of Del(5q). Conference. 57th American Society of Hematology Annual Meeting. Orlando, Florida, US.
- 2014. Myelodysplastic syndromes with i(17)(q10) and prognostic implications of mutations of TP53 and SETBP1. Poster. 56th American Society of Hematology Annual Meeting. San Francisco, California, US.
- 2013. Whole-Exome Sequencing in Myelodysplastic Syndrome with 5q- and normal karyotype. Poster. 55th American Society of Hematology Annual Meeting. New Orleans, Louisiana, US.
International Presentations
- 2025. Therapeutically Targeting Heme-Regulated Inhibitor Kinase Improves Aberrant Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts or Sickle Cell Disease. Conference. 4th Translational Research conference: Pathophysiology and Clinical Advances in Sickle Cell Disease and Thalassemia. Malahide (Dublin), IE.
- 2021. Single-Cell-Level Analysis of SF3B1-Mutant Myelodysplastic Syndrome With Ringed Sideroblasts. Conference. 16th International Congress on Myelodysplastic Syndromes. Toronto, CA.
- 2017. Mutational Signature and Clonal Architecture of Low Risk Myelodysplastic. Conference. 14th International Symposium on Myelodysplastic Syndromes. Valencia, ES.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | Targeting ineffective erythropoiesis in myelodysplastic syndromes with ringed sideroblasts |
| Funding Source: | CPRIT Award |
| Role: | Key |
| Date: | 2025 - 2026 |
| Title: | Therapeutically targeting the EIF2AK1 pathway to overcome ineffective erythroid differentiation in myelodysplastic syndromes with ringed sideroblasts and SF3B1 mutations |
| Funding Source: | The Taub Foundation |
| Role: | Key |
| Date: | 2023 - 2026 |
| Title: | Targeting the EIF2AK1 signaling pathway to overcome ineffective erythropoiesis in myelodysplastic syndrome with ringed sideroblasts and SF3B1 mutations |
| Funding Source: | Edward P. Evans Foundation |
| Role: | Key |
| Date: | 2023 - 2024 |
| Title: | Targeting the EIF2AK1 signaling pathway to overcome ineffective erythropoiesis in myelodysplastic syndrome |
| Funding Source: | , The University of Texas MD Anderson Cancer Center |
| Role: | Key |
| Date: | 2022 - 2023 |
| Title: | EIF2AK1-mediated signaling drives SF3B1 mutation-induced arrest in terminal erythroid differentiation in myelodysplastic syndrome with ringed sideroblasts |
| Funding Source: | Leukemia SPORE Career Enhancement Program |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | Targeting IL1 beta in clonal cytopenia of undetermined significance and low risk myelodysplastic syndrome |
| Funding Source: | Edward P. Evans Foundation |
| Role: | Key |
Selected Publications
Peer-Reviewed Articles
- Rodriguez-Sevilla, JJ, Ganan Gomez, I, Kumar, B, Thongon, N, Ma, F, Chien, KS, Kim, YJ, Yang, H, Loghavi, S, Tan, R, Ademà Llobet, V, Li, Z, Tanaka, T, Uryu, H, Kanagal Shamanna, R, Al-Atrash, G, Bejar, R, Banerjee, PP, Lynn Cha, S, Montalban Bravo, G, Dougherty, M, Fernandez Laurita, MC, Wheeler, N, Jia, B, Papapetrou, EP, Izzo, F, Duenas, DE, McAllen, S, Gu, Y, Todisco, G, Ficara, F, Della Porta, M, Jain, A, Takahashi, K, Dwyer, KC, Halene, S, Bertilaccio, MS, Garcia-Manero, G, Daher, M, Colla, S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40216768.
- Rodriguez-Sevilla, JJ, Ganan Gomez, I, Ma, F, Chien, KS, Del Rey, M, Loghavi, S, Montalban Bravo, G, Ademà Llobet, V, Wildeman, B, Kanagal Shamanna, R, Bazinet, A, Chifotides, H, Thongon, N, Calvo, X, Hernández, JM, Díez-Campelo, M, Garcia-Manero, G, Colla, S. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38499526.
- Rodriguez-Sevilla, JJ, Ademà Llobet, V, Chien, KS, Loghavi, S, Ma, F, Yang, H, Montalban-Bravo, G, Huang, X, Calvo, X, Joseph, J, Bodden, K, Garcia-Manero, G, Colla, S. The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39537648.
- Thongon, N, Ma, F, Baran, N, Lockyer, P, Liu, J, Jackson, C, Rose, A, Furudate, K, Wildeman, B, Marchesini, M, Marchica, V, Storti, P, Todaro, G, Ganan Gomez, I, Ademà Llobet, V, Rodriguez-Sevilla, JJ, Qing, Y, Ha, MJ, Fonseca, R, Stein, C, Class, CA, Tan, L, Attanasio, S, Garcia-Manero, G, Giuliani, N, Berrios Nolasco, DA, Santoni, A, Cerchione, C, Bueso-Ramos, CE, Konopleva, M, Lorenzi, PL, Takahashi, K, Manasanch, EE, Sammarelli, G, Kanagal Shamanna, R, Viale, A, Chesi, M, Colla, S. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38331987.
- Montalban Bravo, G, Thongon, N, Rodriguez-Sevilla, JJ, Ma, F, Ganan Gomez, I, Yang, H, Kim, YJ, Ademà Llobet, V, Wildeman, B, Tanaka, T, Darbaniyan, F, Al-Atrash, G, Dwyer, KC, Loghavi, S, Kanagal Shamanna, R, Song, X, Zhang, J, Takahashi, K, Kantarjian, HM, Garcia-Manero, G, Colla, S. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38781960.
- Mori, M, Kubota, Y, Durmaz, A, Gurnari, C, Goodings, C, Ademà Llobet, V, Ponvilawan, B, Bahaj, WS, Kewan, T, LaFramboise, T, Meggendorfer, M, Haferlach, C, Barnard, J, Wlodarski, M, Visconte, V, Haferlach, T, Maciejewski, JP. Genomics of deletion 7 and 7q in myeloid neoplasm. Leukemia 37(10):2082-2093, 2023. e-Pub 2023. PMID: 37634012.
- Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv, 2023. e-Pub 2023. PMID: 37066354.
- Durmaz A, Gurnari C, Hershberger CE, Pagliuca S, Daniels N, Awada H, Awada H, Adema V, Mori M, Ponvilawan B, Kubota Y, Kewan T, Bahaj WS, Barnard J, Scott J, Padgett RA, Haferlach T, Maciejewski JP, Visconte V. A multimodal analysis of genomic and RNA splicing features in myeloid malignancies. iScience 26(3):106238, 2023. e-Pub 2023. PMID: 36926651.
- Thongon N, Ma F, Lockyer P, Baran N, Liu J, Jackson C, Rose A, Wildeman B, Marchesini M, Marchica V, Storti P, Giuliani N, Ganan-Gomez I, Adema V, Qing Y, Ha M, Fonseca R, Class C, Tan L, Kanagal-Shamanna R, Nolasco DB, Cerchione C, Montalban-Bravo G, Santoni A, Bueso-Ramos C, Konopleva M, Lorenzi P, Garcia-Manero G, Manasanch E, Viale A, Chesi M, Colla S. Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma. bioRxiv, 2023. e-Pub 2023. PMID: 36865225.
- Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov 3(6):554-567, 2022. e-Pub 2022. PMID: 35926182.
- Kongkiatkamon S, Terkawi L, Guan Y, Adema V, Hasipek M, Dombrovski T, Co M, Walter W, Awada H, Parker Y, Hutter S, Pagliuca S, Gurnari C, Rogers HJ, Meggendorfer M, Lindner DJ, Haferlach T, Visconte V, LaFramboise T, Jha BK, Maciejewski JP. Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. Leukemia 36(8):2086-2096, 2022. e-Pub 2022. PMID: 35761024.
- Adema V, Palomo L, Walter W, Mallo M, Hutter S, La Framboise T, Arenillas L, Meggendorfer M, Radivoyevitch T, Xicoy B, Pellagatti A, Haferlach C, Boultwood J, Kern W, Visconte V, Sekeres M, Barnard J, Haferlach T, Solé F, Maciejewski JP. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. EBioMedicine 80:104059, 2022. e-Pub 2022. PMID: 35617825.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. e-Pub 2022. PMID: 35484266.
- Kongkiatkamon S, Pagliuca S, Adema V, Nagata Y, Kerr CM, Walter W, Awada H, Hutter S, Gurnari C, Rogers HJ, Meggendorfer M, Saunthararajah Y, Haferlach T, Visconte V, Maciejewski JP. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia 36(4):1185-1188, 2022. e-Pub 2022. PMID: 34845315.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
- Adema V, Colla S. EZH2 Inhibitors: The Unpacking Revolution. Cancer Res 82(3):359-361, 2022. e-Pub 2022. PMID: 35110396.
- Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho DF, Zalcberg IR, Ahn JS, Kim HJ, Kim DDH, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, Maciejewski JP, Visconte V. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv 6(1):100-107, 2022. e-Pub 2022. PMID: 34768283.
- Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun 12(1):6850, 2021. e-Pub 2021. PMID: 34824242.
- Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol 39(33):3737-3746, 2021. e-Pub 2021. PMID: 34406850.
- Awada H, Kerr CM, Durmaz A, Adema V, Gurnari C, Pagliuca S, Zawit M, Kongkiatkamon S, Rogers HJ, Saunthararajah Y, Sekeres MA, Carraway H, Maciejewski JP, Visconte V. Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. Leukemia 35(11):3324-3328, 2021. e-Pub 2021. PMID: 33603144.
- Gurnari C, Durrani J, Pagliuca S, Kishtagari A, Awada H, Kerr CM, Adema V, Kongkiatkamon S, Lichtin AE, Patel BJ, Visconte V, Sekeres MA, Cook JR, Maciejewski JP. Novel invariant features of Good syndrome. Leukemia 35(6):1792-1796, 2021. e-Pub 2021. PMID: 33414481.
- Hershberger CE, Moyer DC, Adema V, Kerr CM, Walter W, Hutter S, Meggendorfer M, Baer C, Kern W, Nadarajah N, Twardziok S, Sekeres MA, Haferlach C, Haferlach T, Maciejewski JP, Padgett RA. Complex landscape of alternative splicing in myeloid neoplasms. Leukemia 35(4):1108-1120, 2021. e-Pub 2021. PMID: 32753690.
- Hershberger CE, Moyer DC, Adema V, Kerr CM, Walter W, Hutter S, Meggendorfer M, Baer C, Kern W, Nadarajah N, Twardziok S, Sekeres MA, Haferlach C, Haferlach T, Maciejewski JP, Padgett RA. Correction: complex landscape of alternative splicing in myeloid neoplasms. Leukemia 35(4):1226, 2021. e-Pub 2021. PMID: 33714977.
- Guan Y, Tiwari AD, Phillips JG, Hasipek M, Grabowski DR, Pagliuca S, Gopal P, Kerr CM, Adema V, Radivoyevitch T, Parker Y, Lindner DJ, Meggendorfer M, Abazeed M, Sekeres MA, Mian OY, Haferlach T, Maciejewski JP, Jha BK. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. Blood Cancer Discov 2(2):146-161, 2021. e-Pub 2021. PMID: 33681816.
- Adema V, Khouri J, Ni Y, Rogers HJ, Kerr CM, Awada H, Nagata Y, Kuzmanovic T, Advani AS, Gerds AT, Mukherjee S, Nazha A, Saunthararajah Y, Madanat Y, Patel BJ, Solé F, Nawrocki ST, Carew JS, Sekeres MA, Maciejewski JP, Visconte V, Carraway HE. Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. Leuk Lymphoma 62(3):735-738, 2021. e-Pub 2021. PMID: 33140678.
- Palomo L, Meggendorfer M, Hutter S, Twardziok S, Ademà V, Fuhrmann I, Fuster-Tormo F, Xicoy B, Zamora L, Acha P, Kerr CM, Kern W, Maciejewski JP, Solé F, Haferlach C, Haferlach T. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood 136(16):1851-1862, 2020. e-Pub 2020. PMID: 32573691.
- Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, Kizilors A, Cervera J, Lea N, Ferrero D, Germing U, Hildebrandt B, Martínez ABV, Santini V, Sanz GF, Solé F, Mufti GJ. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia 34(9):2441-2450, 2020. e-Pub 2020. PMID: 32066866.
- Li ST, Wang J, Wei R, Shi R, Adema V, Nagata Y, Kerr CM, Kuzmanovic T, Przychodzen B, Sole F, Maciejewski JP, LaFramboise T. Rare germline variant contributions to myeloid malignancy susceptibility. Leukemia 34(6):1675-1678, 2020. e-Pub 2020. PMID: 31911633.
- Adema V, Palomo L, Toma A, Kosmider O, Fuster-Tormo F, Benito R, Salgado R, Such E, Larrayoz MJ, Xicoy B, Hernandez-Sanchez JM, Maietta P, Neef A, Fontenay M, Ibañez M, Diez-Campelo M, Alvarez S, Maciejewski JP, Fenaux P, Sole F. Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide. Br J Haematol 189(4):e133-e137, 2020. e-Pub 2020. PMID: 32147816.
- Durrani J, Awada H, Kishtagari A, Visconte V, Kerr C, Adema V, Nagata Y, Kuzmanovic T, Hong S, Patel B, Nazha A, Lichtin A, Mukherjee S, Saunthararajah Y, Carraway H, Sekeres M, Maciejewski JP. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia 34(3):957-962, 2020. e-Pub 2020. PMID: 31624375.
- Awada H, Rahman S, Durrani J, Asad MF, Kerr CM, Adema V, Kishtagari A, Graham A, Snider CA, Kongkiatkamon S, Nagata Y, Patel BJ, Carraway HE, Sekeres MA, Maciejewski JP, Visconte V. Leukemia evolving from paroxysmal nocturnal hemoglobinuria. Leukemia 34(1):327-330, 2020. e-Pub 2020. PMID: 31431736.
- Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP. Distinct clinical and biological implications of CUX1 in myeloid neoplasms. Blood Adv 3(14):2164-2178, 2019. e-Pub 2019. PMID: 31320321.
- Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch CM, Advani A, Przychodzen B, Makhoul A, Awada H, Maciejewski JP, Sekeres MA, Nazha A. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leuk Lymphoma 60(6):1587-1590, 2019. e-Pub 2019. PMID: 30618304.
- Kerr CM, Clemente MJ, Chomczynski PW, Przychodzen B, Nagata Y, Adema V, Visconte V, Lichtin AE, Mustjoki S, Radivoyevitch T, Sekeres MA, Maciejewski JP. Subclonal STAT3 mutations solidify clonal dominance. Blood Adv 3(6):917-921, 2019. e-Pub 2019. PMID: 30898763.
- Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv 3(3):339-349, 2019. e-Pub 2019. PMID: 30709865.
- Nagata Y, Narumi S, Guan Y, Przychodzen BP, Hirsch CM, Makishima H, Shima H, Aly M, Pastor V, Kuzmanovic T, Radivoyevitch T, Adema V, Awada H, Yoshida K, Li S, Sole F, Hanna R, Jha BK, LaFramboise T, Ogawa S, Sekeres MA, Wlodarski MW, Cammenga J, Maciejewski JP. Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. Blood 132(21):2309-2313, 2018. e-Pub 2018. PMID: 30322869.
- Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP. Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia 32(8):1751-1761, 2018. e-Pub 2018. PMID: 29795413.
- Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Haase D. Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. Am J Hematol 93(6):E152-E154, 2018. e-Pub 2018. PMID: 29575088.
- Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, de Haro N, Mallo M, Xicoy B, Zamora L, Solé F. Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients. Biopreserv Biobank 15(4):360-365, 2017. e-Pub 2017. PMID: 28586236.
- Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget 7(35):57021-57035, 2016. e-Pub 2016. PMID: 27486981.
- Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. Am J Hematol 91(2):185-92, 2016. e-Pub 2016. PMID: 26509444.
- Adema V, Larráyoz MJ, Calasanz MJ, Palomo L, Patiño-García A, Agirre X, Hernández-Rivas JM, Lumbreras E, Buño I, Martinez-Laperche C, Mallo M, García O, Álvarez S, Blazquez B, Cervera J, Luño E, Valiente A, Vallespí MT, Arenillas L, Collado R, Pérez-Oteyza J, Solé F. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations. Br J Haematol 171(1):137-41, 2015. e-Pub 2015. PMID: 25716545.
- Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, García-Cerecedo T, López R, Talavera E, Fernández-Ruiz S, Ademà V, Marugan I, Luño E, Sanzo C, Vallespí T, Arenillas L, Marco Buades J, Batlle A, Buño I, Martín Ramos ML, Blázquez Rios B, Collado Nieto R, Vargas MT, González Martínez T, Sanz G, Solé F, Study (GESMD) SGFM, Cytogenetics (Gcecgh) SGFC. Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. Leuk Lymphoma 56(11):3183-8, 2015. e-Pub 2015. PMID: 25754580.
- Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26(4):509-20, 2014. e-Pub 2014. PMID: 25242043.
- Ademà V, Torres E, Solé F, Serrano S, Bellosillo B. Paraffin treasures: do they last forever?. Biopreserv Biobank 12(4):281-3, 2014. e-Pub 2014. PMID: 25075953.
- Adema V, Bejar R. What lies beyond del(5q) in myelodysplastic syndrome?. Haematologica 98(12):1819-21, 2013. e-Pub 2013. PMID: 24323981.
- Ademà V, Hernández JM, Abáigar M, Lumbreras E, Such E, Calull A, Dominguez E, Arenillas L, Mallo M, Cervera J, Marugán I, Tormo M, García F, González T, Luño E, Sanzo C, Martín ML, Fernández M, Costa D, Blázquez B, Barreña B, Marco F, Batlle A, Buño I, Martínez-Laperche C, Noriega V, Collado R, Ivars D, Carbonell F, Vallcorba I, Melero J, Delgado E, Vargas MT, Grau J, Salido M, Espinet B, Melero C, Florensa L, Pedro C, Solé F. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?. Leuk Res 37(4):416-21, 2013. e-Pub 2013. PMID: 23337401.
- Valcárcel D, Ademà V, Solé F, Ortega M, Nomdedeu B, Sanz G, Luño E, Cañizo C, de la Serna J, Ardanaz M, Marco V, Collado R, Grau J, Montoro J, Mallo M, Vallespí T. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 31(7):916-22, 2013. e-Pub 2013. PMID: 23319689.
- Nino KE, Adema V, Gray AE, Cowan CM, Schleicher WE, Hosseini SM, Bennett SN, Patel SB, Moreira S, Danis EP, Ma F, Lin HY, Young TN, Anderson CC, Sharma D, Varesi A, Filippi MD, Ito K, Dawlaty MM, Huang G, Reisz JA, Xie SZ, Chan SM, Tan L, Garcia-Manero G, Chien KS, Ganan-Gomez I, D'Alessandro A, Colla S, Pietras EM. Aberrant oxidative metabolism selects for TET2-deficient hematopoietic stem and progenitor cells.
Review Articles
- Adema V, Pesce F, Garcia-Manero G, Santini V, Colla S. Understanding the Molecular Mechanisms Underlying Anemia in Myelodysplastic Syndromes: From Erythropoiesis to New Therapeutic Approaches. e-Pub 2026.
- Rodriguez-Sevilla JJ, Adema V, Garcia-Manero G, Colla S. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Rep Med 4(2):100940, 2023. e-Pub 2023. PMID: 36787738.
Letters to the Editor
- Balasubramanian, SK, Aly, M, Nagata, Y, Bat, T, Przychodzen, B, Hirsch, CM, Ademà Llobet, V, Visconte, V, Kuzmanovic, T, Radivoyevitch, T, Nazha, A, Mukherjee, S, Sekeres, MA, Maciejewski, J. Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. Leukemia 32: 550-553, 2018.
- Nazha, A, Al-Issa, K, Hamilton, BK, Radivoyevitch, T, Gerds, A, Mukherjee, S, Ademà Llobet, V, Zarzour, A, Abuhadra, NK, Patel, BJ, Hirsch, CM, Advani, A, Przychodzen, B, Carraway, H, Maciejewski, J, Sekeres, MA. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia 31: 2848-2850, 2017.
- Negoro, E, Radivoyevitch, T, Polprasert, C, Ademà Llobet, V, Hosono, N, Makishima, H, Przychodzen, B, Hirsch, CM, Clemente, MJ, Nazha, A, Santini, V, Mcgraw, K, List, A, Solé, F, Sekeres, MA, Maciejewski, J. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia 30: 2405-2409, 2016.
- Salido, M, Martinez-Avilés, L, Ademà Llobet, V, Ferrer, A, Espinet, B, Garcia, M, Salar, A, Besses, C, Florensa, L, Serrano, S, Bellosillo, B, Solé, F. Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma. Leukemia Research 35: e23-e24, 2011.
Patient Reviews
CV information above last modified July 22, 2026